Repare Therapeutics Inc (RPTX)

Etorro trading 970x250
Repare Therapeutics Inc (RPTX) Logo

About Repare Therapeutics Inc

Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada. The company use its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing CCNE1-SL inhibitor, a proprietary drug discovery program for tumors with amplification of CCNE1; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada. Address: 7210 Frederick-Banting, Montreal, QC, Canada, H4S 2A1

Repare Therapeutics Inc News and around…

Latest news about Repare Therapeutics Inc (RPTX) common stock and company :

58 Biggest Movers From Yesterday
24 May, 2022 FinancialContent

Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) gained 234.2% to close at $1.27 after the company announced it sold its ...

30 Stocks Moving In Monday's Mid-Day Session
23 May, 2022 FinancialContent

Gainers Evolve Transition Infrastructure LP (NYSE: SNMP) shares rose 29.2% to $0.6699 after jumping around 14% on Friday. Forge ...

We Did The Math SMMV Can Go To $42
16 May, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $41.86 per unit.

Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day
09 May, 2022 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the virtual 2022 Guggenheim Synthetic Lethality Day on Monday, May 16, 2022 at 9:00 a.m. Eastern Time.

Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates
06 May, 2022 Yahoo! Finance

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.74% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
05 May, 2022 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022.

Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
05 May, 2022 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates
04 May, 2022 Yahoo! Finance

Global Blood (GBT) delivered earnings and revenue surprises of 2.33% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification
20 Apr, 2022 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that preclinical data demonstrating inhibition of CCNE1-amplified tumor growth in vivo by selective inhibition of PKMYT1 using RP-6306, a first-in-class small molecule candidate targeting PKMYT1, were published in Nature. SNIPRx®, Repare’s proprietary, genome-wide, CRISPR-based screening approach, was used to uncover CCNE1 amplification as synthetic lethal to PKMYT1 inhibition.

Repare Therapeutics Inc. (RPTX) Stock Jumps 9.1%: Will It Continue to Soar?
13 Apr, 2022 Yahoo! Finance

Repare Therapeutics Inc. (RPTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2022
12 Apr, 2022 FinancialContent

Upgrades TD Securities upgraded the previous rating for Louisiana-Pacific Corp (NYSE:LPX) from Hold to Buy. In the fourth quarter, ...

Repare Therapeutics Shares Dip After Updated RP-3500 Data In Solid Tumors
12 Apr, 2022 FinancialContent

Repare Therapeutics Inc(NASDAQ: RPTX)presented updated datafrom its ongoing Phase 1/2 TRESR trial of RP-3500 for ...

The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
12 Apr, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Aeglea Shares Additional ...

Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting
11 Apr, 2022 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented updated data from its ongoing Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific synthetic-lethal genomic alterations including those in the ATM gene (Ataxia-Telangiectasia mutated kinase) at the 2022 AACR Annual Meeting.

The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
10 Apr, 2022 FinancialContent

Biotech stocks managed to carve out modest gains for the week endingApril 8, defying the broader market weakness. The defensive ...

Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting
08 Apr, 2022 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it has been selected for an oral presentation of clinical data from its ongoing Phase 1/2 TRESR (Treatment Enabled by SNIPRx) trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase), as well as two additional poster presentations at the upcoming 2022 AACR Annual Meeting held in New Orleans on April 8-13, 2022.

Implied SMMV Analyst Target Price: $43
31 Mar, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $42.93 per unit.

Goldman Sachs Bullish on These 2 Stocks for 80% Upside (Or More)
30 Mar, 2022 Yahoo! Finance

The markets started 2022 with heavy losses – but the last two weeks have seen sharp gains that have lifted stocks back out of correction territory. The S&P 500 is up 11% from its March 14 trough, while the NASDAQ, which had fallen farther, had gained 16% in the last couple of weeks. Goldman Sachs' David Kostin sees an interesting pattern, as we go forward. According to the chief US equity strategist, institutional investors will pull back, while households will be the major source of purchase ac

Repare Therapeutics Enters Oversold Territory (RPTX)
14 Mar, 2022 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Repare Therapeutics to Present Comprehensive Phase 1 Monotherapy Data From the Phase 1/2 TRESR RP-3500 Clinical Trial and SNiPDx Panel at the 2022 AACR Annual Meeting
08 Mar, 2022 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced it has been selected for an oral presentation of clinical data from its ongoing Phase 1/2 TRESR trial of RP-3500 and a poster presentation of initial discovery and validation data of the novel Synthetic Lethal Interactions for Precision Diagnostics (SNiPDx) panel to understand allelic status of STEP2 genes at the upcoming 2022 AACR Annual Meeting, being held in New Orleans on April 8-13, 2022.

Repare Therapeutics Highlights Early RP-3500 Data In Solid Tumor Patients
07 Mar, 2022 FinancialContent

Repare Therapeutics Inc(NASDAQ: RPTX) has announced the presentation ofmonotherapy dose selection and safety datafrom ...

Repare Therapeutics Presents RP-3500 Dose Selection Phase 1 Monotherapy Safety Data from the Phase 1/2 TRESR Clinical Trial at the 2022 ESMO Targeted Anticancer Therapies Congress
07 Mar, 2022 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the presentation of monotherapy dose selection and safety data from its Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500 at the 2022 ESMO Targeted Anticancer Therapies (TAT) Congress. RP-3500 is a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) in development for the treatment of solid tumors with specific synthetic-lethal genomic alterations, including those in the ATM gene (Ataxia-Telangiectasia mutated kinase).

Repare Therapeutics (NASDAQ:RPTX) shareholders have endured a 45% loss from investing in the stock a year ago
04 Mar, 2022 Yahoo! Finance

Investors can approximate the average market return by buying an index fund. While individual stocks can be big...

Repare Therapeutics Inc. (RPTX) Reports Q4 Loss, Tops Revenue Estimates
01 Mar, 2022 Yahoo! Finance

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.67% and 94.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
01 Mar, 2022 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Atara Biotherapeutics (ATRA) Reports Q4 Loss, Lags Revenue Estimates
28 Feb, 2022 Yahoo! Finance

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -60% and 84.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
03 Feb, 2022 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in two virtual investor conferences in February. Details are as follows:

RSI Alert: Repare Therapeutics (RPTX) Now Oversold
07 Jan, 2022 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Stocks That Hit 52-Week Lows On Friday
07 Jan, 2022 FinancialContent

Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana ...

Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022
07 Jan, 2022 FinancialContent

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today provided a corporate update and highlighted key milestones anticipated in 2022.

Repare Therapeutics Inc (RPTX) is a NASDAQ Common Stock listed in , ,

970x250